Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04722770 · ClinicalTrials.gov registry record
Clinical Development of Deep Learning for the OtoSight
A clinical trial, sponsored by PhotoniCare.
- Completed
- Registry status
- 188
- Enrollment target
NCT04722770: Completed study, sponsored by PhotoniCare.
NCT04722770 is a clinical trial that has completed, run by PhotoniCare. The registered enrollment target is 188 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04722770 has completed, sponsored by PhotoniCare.
- COMPLETED
- Registry status
- 188 participants
- Enrollment target
Study Summary
The objective of this study is to clinically develop and evaluate a machine learning approach to improve the performance and data interpretation of the PhotoniCare OtoSight Middle Ear Scope in pediatric patients presenting at the primary care office for suspected ear infections. In this observational study, results of OtoSight imaging will not affect patient standard of care.
Primary Outcome
Optical coherence tomography imaging to evaluate the middle ear.
Interventions
- DEVICE PhotoniCare OtoSight Middle Ear Scope
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 188 participants |
| Start Date | 2021-01-19 |
| Est. Completion | 2023-08-31 |
What the finished NCT04722770 record still lists
NCT04722770 is an observational study that tracks outcomes without assigning an intervention. The registered 188 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which PhotoniCare OtoSight Middle Ear Scope is the first listed.
NCT04722770 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04722770 about?
NCT04722770 is a clinical study titled "Clinical Development of Deep Learning for the OtoSight". The objective of this study is to clinically develop and evaluate a machine learning approach to improve the performance and data interpretation of the PhotoniCare OtoSight Middle Ear Scope in pediatric patients presenting at the primary care office for suspected ear infections. In this observationa...
What is the current status of trial NCT04722770?
This trial is currently completed. The enrollment target is 188 participants. The study started on 2021-01-19. Estimated completion is 2023-08-31.
What interventions are being tested in trial NCT04722770?
The interventions under investigation include: PhotoniCare OtoSight Middle Ear Scope (DEVICE).
Who is sponsoring clinical trial NCT04722770?
This trial is sponsored by PhotoniCare, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03422198 · 188 participants · Phase 3
Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
- NCT04469790 · 188 participants · NA
Effects of Multi-day Interruptions in Sitting on Type 2 Diabetes-relevant Outcomes in Children
- NCT04671667 · 188 participants · Phase 2
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
- NCT04853251 · 188 participants · Phase 4
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI